Zachary Prensky - 10 Sep 2025 Form 3 Insider Report for LB PHARMACEUTICALS INC

Role
Director
Signature
/s/ Marc Panoff, Attorney-in-Fact
Issuer symbol
LBRX on Nasdaq
Transactions as of
10 Sep 2025
Net transactions value
$0
Form type
3
Filing time
10 Sep 2025, 19:21:52 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PRENSKY ZACHARY Director C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK /s/ Marc Panoff, Attorney-in-Fact 09 Sep 2025 0001167585

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LBRX Common Stock 315 10 Sep 2025 Direct
holding LBRX Common Stock 60,959 10 Sep 2025 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LBRX Employee Stock Option (Right to Buy) 10 Sep 2025 Common Stock 3,944 $64.15 Direct F2
holding LBRX Employee Stock Option (Right to Buy) 10 Sep 2025 Common Stock 896 $69.72 Direct F2
holding LBRX Employee Stock Option (Right to Buy) 10 Sep 2025 Common Stock 1,255 $69.72 Direct F2
holding LBRX Employee Stock Option (Right to Buy) 10 Sep 2025 Common Stock 17,929 $41.84 Direct F3
holding LBRX Employee Stock Option (Right to Buy) 10 Sep 2025 Common Stock 53,787 $41.84 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held by The Kybartai Trust, of which the Reporting Person is both a trustee and partial beneficiary. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F2 Immediately exercisable.
F3 One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4 One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.